HUALAN BIOLOGICAL VACCINE INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.28 CNY | -8.87% |
|
-6.13% | -23.45% |
| Apr. 25 | Hualan Biological Vaccine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 01 | Hualan Biological Vaccine Inc. Proposes Final Cash Dividend for 2023 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 17,832 | 16,680 | 12,768 | - | - |
| Enterprise Value (EV) 1 | 17,832 | 16,680 | 12,768 | 12,768 | 12,768 |
| P/E ratio | 33.7 x | 19.5 x | 12.3 x | 9.96 x | 7.88 x |
| Yield | - | 2.16% | 3.34% | 3.95% | 5.12% |
| Capitalization / Revenue | 9.77 x | 6.92 x | 4.36 x | 3.59 x | 2.98 x |
| EV / Revenue | 9.77 x | 6.92 x | 4.36 x | 3.59 x | 2.98 x |
| EV / EBITDA | 24.3 x | 14.4 x | 9.63 x | 7.8 x | 6.32 x |
| EV / FCF | - | 20.2 x | 16.8 x | 15.5 x | 16.6 x |
| FCF Yield | - | 4.95% | 5.95% | 6.44% | 6.03% |
| Price to Book | 3.24 x | 2.66 x | 1.8 x | 1.57 x | 1.33 x |
| Nbr of stocks (in thousands) | 600,015 | 600,015 | 600,015 | - | - |
| Reference price 2 | 29.72 | 27.80 | 21.28 | 21.28 | 21.28 |
| Announcement Date | 3/29/23 | 3/29/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,830 | 1,826 | 2,410 | 2,932 | 3,561 | 4,290 |
| EBITDA 1 | - | 733.2 | 1,155 | 1,326 | 1,637 | 2,020 |
| EBIT 1 | - | 592.6 | 1,010 | 1,215 | 1,492 | 1,900 |
| Operating Margin | - | 32.46% | 41.9% | 41.46% | 41.91% | 44.28% |
| Earnings before Tax (EBT) 1 | - | 589.5 | 1,007 | 1,214 | 1,490 | 1,897 |
| Net income 1 | - | 519.6 | 860 | 1,036 | 1,283 | 1,620 |
| Net margin | - | 28.46% | 35.68% | 35.34% | 36.04% | 37.78% |
| EPS 2 | 1.150 | 0.8807 | 1.428 | 1.730 | 2.138 | 2.700 |
| Free Cash Flow 1 | - | - | 825.5 | 759.2 | 821.9 | 770.3 |
| FCF margin | - | - | 34.25% | 25.9% | 23.08% | 17.96% |
| FCF Conversion (EBITDA) | - | - | 71.48% | 57.26% | 50.2% | 38.13% |
| FCF Conversion (Net income) | - | - | 95.99% | 73.28% | 64.05% | 47.53% |
| Dividend per Share 2 | - | - | 0.6000 | 0.7100 | 0.8400 | 1.090 |
| Announcement Date | 3/29/22 | 3/29/23 | 3/29/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 826 | 759 | 822 | 770 |
| ROE (net income / shareholders' equity) | - | 10.6% | 14.7% | 14.9% | 16% | 16.9% |
| ROA (Net income/ Total Assets) | - | - | 11.4% | 12.1% | 13.3% | 15.1% |
| Assets 1 | - | - | 7,535 | 8,598 | 9,673 | 10,732 |
| Book Value Per Share 2 | - | 9.160 | 10.40 | 11.80 | 13.50 | 16.00 |
| Cash Flow per Share 2 | - | 0.4800 | 1.480 | 1.690 | 1.960 | 2.440 |
| Capex 1 | - | 92.3 | 62.5 | 171 | 168 | 195 |
| Capex / Sales | - | 5.06% | 2.59% | 5.83% | 4.71% | 4.55% |
| Announcement Date | 3/29/22 | 3/29/23 | 3/29/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
21.28
CNY
Average target price
33.2
CNY
Spread / Average Target
+56.02%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -23.45% | 1.76B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 301207 Stock
- Financials Hualan Biological Vaccine Inc.
